BioM Pharma Day: Daiichi Sankyo seeks expertise of Bavarian biotech companies

Daiichi Sankyo representatives at the BioM Pharma Day (from left to right): Takahiro Nagayama, Tokio BD Specialty Medicines; Shinji Ashida, Tokio BD Oncology; Frank Simmersbach, EU BD Specialty Medicines; Kiichiro Yano, Tokio Global Scientific Innovation Team; Hannah Seitz, EU BD Specialty & Oncology; Ines Schwippl, EU BD Oncology; Michael Flaschen, Senior Vice President Global External Innovation; Max Pöhlmann, Clustermanager, BioM; Stephanie Wehnelt, Head of International Affairs, BioM; Horst Domdey, Geschäftsführer, BioM; Philipp Hoffmann, Head of EU BD. © BioM

The Japanese pharmaceutical company Daiichi Sankyo met eight young and innovative Bavarian biotech companies at the Daiichi Sankyo BioM Pharma Day in Munich as part of its European tour on the occasion of BIO-Europe to foster networking, increase the understanding of technology potentials and discuss mutual interests for future translational collaboration. The Munich companies were from different biotech and pharma business fields and consisted of an exciting mix of startups and academic project groups.

Following BIO-Europe 2022 in Leipzig, a delegation from Daiichi Sankyo, consisting of representatives from Daiichi Sankyo Co., Ltd. of Japan, Daiichi Sankyo, Inc. of the U.S., and Daiichi Sankyo Europe GmbH of Munich, Germany, visited BioM Biotech Cluster Development GmbH, which had organized and hosted the Daiichi Sankyo BioM Pharma Day in Planegg/Martinsried, to meet in person with selected “rising stars” from the Biotechnology Cluster Bavaria.

The Pharma Day was preceded by a wish list of interests, provided by Daiichi Sankyo to BioM in advance. Bavarian companies and project groups from various biotech and pharma technology fields were matched to this list, and they could apply with an expression of interest to meet with the Daiichi Sankyo delegation of experts. After careful consideration, eight startups and project groups were selected. The meetings were conducted as consecutive 45-minute one-on-one sessions at BioM's facilities, ensuring confidentiality and privacy.

Both sides were very satisfied with the quality and depth of the discussions.

Dr. Hannah Seitz, co-organizer and BD Specialty & Oncology at Daiichi Sankyo Europe, agreed that

“BioM’s Pharma Day is an effective individual partnering concept, and provides an excellent starting point for cooperation in the near future”.

Unique partnering format for “Big Pharma”

The BioM Pharma Day is a partnering format event that brings together established international pharmaceutical companies (“Big Pharma”) with innovative biotech companies from the Munich and Bavarian biotechnology cluster to meet, network and foster the initiation of future translational collaborations. Mutual interest is clarified in advance, based on a Pharma Wish List. This approach saves both sides time and disappointed expectations. For startups, it accelerates the initiation of cooperation, and for pharma it not only saves scouting time, but also opens access to early developments to which the companies would otherwise not have access.

Interested pharmaceutical companies can contact BioM for their own customized Pharma Day event to get in touch with resident biotech companies.

If you are interested in hosting your own Pharma Day, please contact us at